Actively Recruiting
A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
Led by 3H (Suzhou) Pharmaceuticals Co., Ltd. · Updated on 2026-01-27
130
Participants Needed
2
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations.
CONDITIONS
Official Title
A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to provide written informed consent and comply with study requirements
- Men or women aged 18 years or older at consent
- Histologically or cytologically confirmed surgically unresectable, locally advanced, or metastatic solid tumor
- Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
- Expected survival of at least 12 weeks
- Disease measurable or evaluable by RECIST v1.1 criteria
- Adequate organ function based on laboratory tests
You will not qualify if you...
- Active brain metastases
- Other malignancies within the past 3 years
- Toxicity from prior anti-tumor treatment not recovered to grade 1 or lower
- Clinically significant corneal, retinal disease, or keratopathy
- Clinically significant cardiovascular disorders
- Conditions affecting swallowing or drug absorption such as chronic diarrhea
- Known allergy to study drug or its components
- Assessed by investigator as unsuitable for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
2
ZhongShan Hospital
Shanghai, Shanghai Municipality, China, 200123
Actively Recruiting
Research Team
S
Shuchao Wu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here